Sfbc (NASDAQ:SFCC)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Sfbc Charts. Click Here for more Sfbc Charts.](/p.php?pid=staticchart&s=N%5ESFCC&p=8&t=15)
SFBC International, Inc. (NASDAQ:SFCC), a provider of
drug development services to branded pharmaceutical, biotechnology,
generic drug and medical device companies, confirmed today that it
received a letter from Senator Charles E. Grassley (R-Iowa) requesting
additional information from SFBC. SFBC will fully comply with these
requests for information.
"I first received Senator Grassley's letter, which was dated
February 8, 2006, this afternoon," said Jeffrey P. McMullen, chief
executive officer of SFBC International. "We have fully cooperated
with the Senate committee, and we will continue to do so. Our Company
is deeply committed to ensuring the safety and welfare of study
participants and the reliability of our studies."
The letter stated that its purpose was to follow up on last
month's meeting with the Senate Finance Committee staff and former
SFBC employees. As a follow-up to the meeting on January 11, 2006, the
Committee has requested the company to provide information related to
its standard operating procedures at its Miami facility, institutional
review boards (IRBs) used by SFBC, human resources, and SFBC employees
mentioned in the independent counsel's report dated December 12, 2005,
which can be found at SFBC's website, http://www.sfbci.com. In
addition, staff members of the United States Senate Committee on
Finance requested to interview Arnold Hantman, the company's former
chief executive officer, at a mutually agreed upon time at the
Committee's office.
About SFBC International, Inc.
SFBC International, Inc. provides early through late stage
clinical drug development services to branded pharmaceutical,
biotechnology, generic drug and medical device companies around the
world. SFBC has more than 30 offices located in North America, Europe
(including Central and Eastern Europe), South America, Asia, and
Australia. In early clinical development services, SFBC specializes
primarily in the areas of Phase I and early Phase II clinical trials
and bioanalytical laboratory services, including early clinical
pharmacology. SFBC also provides late stage clinical development
services globally that focus on Phase II through IV clinical trials.
SFBC also offers a range of complementary services, including data
management and biostatistics, central laboratory services, medical and
scientific affairs, regulatory affairs and submissions, and clinical
IT solutions. Additional information is available on SFBC's website at
http://www.sfbci.com.